Aurobindo Pharma has received an approval for the acquisition of 51% equity shares in GLS Pharma, operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of Rs 28.05 crore. This acquisition is undertaken to expand the foothold of the company in Oncology business in the domestic market and inorganic addition to capacity and revenues in oncology business. The completion of the share transfer is estimated before July 31, 2022. The Board of Directors of the Company at its meeting held on June 17, 2022, has approved the same.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.45 |
| Dr. Reddys Lab | 1235.50 |
| Cipla | 1236.00 |
| Zydus Lifesciences | 939.75 |
| Lupin | 2332.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: